District Of Columbia is currently home to 851 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Proton Radiation Therapy Registry
NCT04376229
Recruiting
The Johns Hopkins Proton Therapy center is establishing a registry to capture the full 3D radiation dosimetry delivered to the patient, baseline clinical data, and disease, toxicity and quality of life outcomes. The goal is to have all patients treated at the proton center to be included in the registry to enable future comparisons of treatment outcomes to assist in understanding which patients can benefit from the use of protons.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/30/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Cancer, Therapy-Related
Register for Updates
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
NCT04005339
Recruiting
This is a study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia
Conditions: Advanced Biliary Tract Cancer
Register for Updates
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
NCT03223922
Recruiting
This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/30/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Brain Metastases
Register for Updates
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
NCT02177578
Recruiting
In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care. However, the radiation treatment plan will be modified to deliver an higher than routine radiation dose to the subventricular zone which is an area of the brain that contains stem cells that some scientists believe may contribute to glioblastoma recurrence. The purpose of the study is to see if the tumor is controlled for a longer period of time in patients t... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/30/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Glioblastoma Multiforme
Register for Updates
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117
Recruiting
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2025
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Solid Tumor, MET Alteration
Register for Updates
Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women
NCT07011836
Recruiting
The goal of this clinical trial is to test whether an interactive, video-based patient navigation program can improve cervical cancer screening among African American women who are currently overdue for screening. The main questions it aims to answer are: Can an interactive video navigation tool (mNav), when paired with in-person navigation, improve screening adherence compared to a standard educational video alone? Does the intervention improve knowledge, reduce barriers, and increase intent... Read More
Gender:
FEMALE
Ages:
Between 21 years and 65 years
Trial Updated:
06/27/2025
Locations: Family and Medical Counseling Service, Inc., Washington, District of Columbia
Conditions: Uterine Cervical Neoplasms
Register for Updates
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
NCT06995729
Recruiting
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participants who: * Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms All participants in this study will receive zavegepant as a... Read More
Gender:
ALL
Ages:
Between 6 years and 11 years
Trial Updated:
06/27/2025
Locations: Velocity Clinical Research, Washington DC, Washington, District of Columbia
Conditions: Acute Treatment of Migraine
Register for Updates
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
NCT05644262
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/27/2025
Locations: Georgetown University, Washington, District of Columbia
Conditions: Agitation, Dementia
Register for Updates
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
NCT05575492
Recruiting
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
Gender:
ALL
Ages:
Between 9 years and 25 years
Trial Updated:
06/27/2025
Locations: Velocity Clinical Research (Washington)- PPDS, Washington, District of Columbia
Conditions: Cytomegalovirus
Register for Updates
Technical Development of Cardiovascular Magnetic Resonance Imaging
NCT04927429
Recruiting
Background: In the U.S., over 6.5 million people have heart failure. Researchers want to develop new testing methods for cardiovascular problems using magnetic resonance imaging (MRI) to improve the clinical diagnosis and management of people with heart failure. Objective: To develop and test new methods for imaging the heart and blood vessels using MRI. Eligibility: People ages 18 years and older who are having an MRI of their heart or blood vessels. Healthy volunteers are also needed. De... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/27/2025
Locations: Medstar Washington Hospital Center, Washington, District of Columbia
Conditions: Cardiovascular Disease
Register for Updates
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT06551116
Recruiting
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Georgetown University - Lombardi CCC, Washington, District of Columbia
Conditions: HER2-positive Metastatic Breast Cancer
Register for Updates
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
NCT05452941
Recruiting
The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 new serotypes (types of a bacteria called Streptococcus pneumoniae that cause pneumonia) included in 20vPnC vaccine. This study is seeking participants who: * are male or female ≥65 years of age. * are hospitalized with physician suspicion of community acquired pneumonia (CAP). * have pneumonia conf... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/26/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Pneumonia
Register for Updates